Author

V. Laletin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

D. Olive· 2 shared G. Guittard· 2 shared J. Nunes· 2 shared P.-L. Bernard· 2 shared R. Castellano· 2 shared A. Goubard· 1 shared A. Krug· 1 shared C. Costa Da Silva· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. Olive

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

DOK1 and DOK2 regulate CD8+ T cell signaling and memory formation without affecting tumor cell killing

V. Laletin, P.-L. Bernard, M. Camille, Y. Yamanashi, D. Olive, R. Castellano, G. Guittard, J. Nunes

This study shows that DOK1 and DOK2 inhibit CD8+ T cell memory formation but not tumor cell killing, enhancing TCR signaling without improving cytotoxicity.

bioRxiv · Dec 17, 2021Immunology

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity

P.-L. Bernard, R. Delconte, S. Pastor, V. Laletin, C. Costa Da Silva, A. Goubard, E. Josselin, R. Castellano, A. Krug, J. Vernerey, R. Devillier, D. Olive, E. Verhoeyen, E. Vivier, N. Huntington, , G. Guittard

This study shows that deleting CISH enhances NK cell activation and anti-tumor responses in both mice and human cells, suggesting CISH as a therapeutic target for improving NK cell immunotherapy.

bioRxiv · Mar 16, 2021Immunology